No target in Alzheimer’s disease has generated as much research – nor as much controversy – as the amyloid βeta peptide. Is accumulation of this molecule crucial to the pathology of the disease, or just a misleading epiphenomenon? Mountains of evidence argue for both viewpoints.
Hope grows as another trial testing a drug targeting Aβeta matures, the trials fails and the process begins again. Will the string of failures end with the recent encouraging results of lecanemab? Where would you place your bets? Who will be right in 20 years?
Marc Busche, PhD, MD
Program Leader, UK Dementia Research Institute, University College London
Simon Dujardin, PhD
Principal Scientist, Sanofi
Charles Glabe, PhD
Professor, Molecular Biology and Biochemistry, School of Biological Sciences, University of California, Irvine
Andrew Bush, PhD
Principal, Neuroscience Practice, Lumanity